dc.creatorPérez-Lazo, Giancarlo
dc.creatorSilva-Caso, Wilmer
dc.creatorDel Valle-Mendoza, Juana
dc.creatorMorales-Moreno, Adriana
dc.creatorBallena-López, José
dc.creatorSoto-Febres, Fernando
dc.creatorMartins-Luna, Johanna
dc.creatorCarrillo-Ng, Hugo
dc.creatorDel Valle, Luís J.
dc.creatorKym, Sungmin
dc.creatorAguilar-Luis, Miguel Angel
dc.creatorPeña-Tuesta, Issac
dc.creatorTinco-Valdez, Carmen
dc.creatorIllescas, Luis Ricardo
dc.date.accessioned2021-12-31T13:01:00Z
dc.date.accessioned2024-05-07T02:36:15Z
dc.date.available2021-12-31T13:01:00Z
dc.date.available2024-05-07T02:36:15Z
dc.date.created2021-12-31T13:01:00Z
dc.date.issued2021-11-01
dc.identifier10.3390/antibiotics10111358
dc.identifierhttp://hdl.handle.net/10757/658426
dc.identifier20796382
dc.identifierAntibiotics
dc.identifier2-s2.0-85118939573
dc.identifierSCOPUS_ID:85118939573
dc.identifier0000 0001 2196 144X
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9327381
dc.description.abstractThe impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.
dc.languageeng
dc.publisherMDPI
dc.relationhttps://www.mdpi.com/2079-6382/10/11/1358
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)
dc.sourceRepositorio Academico - UPC
dc.sourceAntibiotics
dc.source10
dc.source11
dc.subjectAntibiotics
dc.subjectCoinfections
dc.subjectCOVID-19
dc.titleIdentification of coinfections by viral and bacterial pathogens in covid-19 hospitalized patients in peru: Molecular diagnosis and clinical characteristics
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución